Imperial Innovations reports strong progress in top three portfolio companies

Imperial Innovations, a technology commercialisation and investment group, on Friday reported 'really good' progress in its top three portfolio companies in its half year results.

Imperial Innovations, a technology commercialisation and investment group, on Friday reported 'really good' progress in its top three portfolio companies in its half year results.

The firm said that in the six months ended January 31st its top three portfolio companies, namely Circassia, Nexeon and Veryan Medical, which represent 52.8% of the value of the portfolio, had all moved closer to commercialisation.

However, this success has yet to feed through into revenues, which remained stable at £1.61m, or pre-tax profits, which dipped from £0.93m to £0.92m.

That said, the company is very confident about its outlook and said it expects to see either the sale of one of its portfolio companies or the sale of one of its products within the next 12 months.

The US Food and Drug Administration (FDA) and the European Medical Agency (EMA) have confirmed that a single successful phase III trial of Circassia's cat allergy product will be sufficient to begin sales, while Veryan Medical has achieved CE mark approval, clearing the way for product launch in Europe.

Nexeon will complete its new manufacturing plant in July and have product available for sale this year.

The group said that it was continuing to focus on its plan to "grow good businesses that have a good syndicate of backers behind them" and is looking to set all of its companies in a position of stength.

In the second half of the year the company anticipates a similar level of investment of £14m.

The group explained that it looks to recognise and realise the value added to its companies at appropriate points, saying it believes that this value creation "will be reflected in higher portfolio valuations in due course".

Chairman of the group Martin Knight said: "Our portfolio companies are developing well, building long-term value as they progress towards commercialisation.

"Our other significant investee companies, including PolyTherics, PsiOxus Therapeutics, Oxford Immunotec, Cortexica and Cell Medica, have also made substantial commercial and technical progress.

"The portfolio has a satisfactory depth and spread of technological activity, which the directors believe bodes well for a sustained and sizeable increase in the valuation of our investments."

The share price was unchanged.

NR

Recommended

Ocado faces a “crunch” year – should you buy or avoid?
Share tips

Ocado faces a “crunch” year – should you buy or avoid?

Ocado was one of the big winners from the pandemic as customers moved online. But now it’s struggling, and losses are growing. So, asks Rupert Hargrea…
27 May 2022
What to buy as the tech-stock bull market crashes
Tech stocks

What to buy as the tech-stock bull market crashes

The decade-long bull market in tech stocks has come to a rapid halt. Investors need to distinguish solid stocks from speculative ones rather than just…
27 May 2022
Share tips of the week – 27 May
Share tips

Share tips of the week – 27 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
27 May 2022
Marks & Spencer shares look cheap – should you buy in?
Retail stocks

Marks & Spencer shares look cheap – should you buy in?

Marks & Spencer shares have been a disappointment for investors for two decades. But with the company now on something of a comeback, Rupert Hargreave…
25 May 2022

Most Popular

The world’s hottest housing markets are faltering – is the UK next?
House prices

The world’s hottest housing markets are faltering – is the UK next?

As interest rates rise, house prices in the world’s most overpriced markets are starting to fall. The UK’s turn will come, says John Stepek. But will …
23 May 2022
Scottish Mortgage Investment Trust has fallen hard. But is now the time to buy?
Investment trusts

Scottish Mortgage Investment Trust has fallen hard. But is now the time to buy?

After a spectacular couple of decades, the Scottish Mortgage Investment Trust has fallen by almost 45% so far this year. Rupert Hargreaves asks if no…
26 May 2022
Is it time to pick up growth stock bargains yet?
Investment strategy

Is it time to pick up growth stock bargains yet?

If you’re thinking of picking up some bargains from the tech stock crash, beware – there are still plenty of “growth traps” out there. John Stepek exp…
26 May 2022